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Abstract Cervical cancer (CC) occurs more frequently in
women who are immunosuppressed, suggesting that both
local and systemic immune abnormalities may be involved
in the evolution of the disease. Costimulatory CD28 and
inhibitory CTLA-4 molecules expressed in T cells play a
key role in the balanced immune responses. There has been
demonstrated a relation between CD28, CTLA-4, and IFN
genes in susceptibility to CC, suggesting their importance
in CC development. Therefore, we assessed the pattern of
CD28 and CTLA-4 expression in T cells from PB of CC
patients with advanced CC (stages III and IV according to
FIGO) compared to controls. We also examined the ability
of PBMCs to secrete IFN-gamma. We found lower
frequencies of freshly isolated and ex vivo stimulated
CD4+CD28+ and CD8+CD28+ T cells in CC patients
than in controls. Loss of CD28 expression was more
pronounced in the CD8+ T subset. Markedly increased
proportions of CTLA-4+ T cells in CC patients before and
after culture compared to controls were also observed. In
addition, patients’ T cells exhibited abnormal kinetics of
surface CTLA-4 expression, with the peak at 24 h of
stimulation, which was in contrast to corresponding normal
T cells, revealing maximum CTLA-4 expression at 72 h of
stimulation. Of note, markedly higher IFN-gamma concen-
trations were shown in supernatants of stimulated PBMCs
from CC patients. Conclusions: Our report shows the
dysregulated CD28 and CTLA-4 expression in PB T cells
of CC patients, which may lead to impaired function of
these lymphocytes and systemic immunosuppression related
to disease progression.
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Introduction
Cervical cancer is one of the most common female
malignancies in Polish women, accounting for 6.4% of
female cancers. It is considered to be an important
immunogenic tumor as the major risk factor for cervical
cancer is infection with specific high-risk types of human
papillomavirus (HPV). Although the incidence of genital
HPV infections is very high, most of them recede
without intervention. In most infected persons the HPV
antigens and neoplastic cells permit the immune system
to eradicate the infection [1]. In fact, about 10% to 20%
of HPV infected individuals develop persistent infection
and are at high risk for progression to high-grade
cervical intraepithelial disease characterized by progressive
ability to resist anti-viral immune defenses. Only in a
limited number of patients does high-risk HPV infection
cause multistep carcinogenesis in normal cervical cells.
These relatively few cancer cases might reflect a
population with ineffectively induced anti-tumor immunity,
predisposing to cancer progression [1]. Indeed, HPV-induced
carcinogenesis and rapid progression of the disease was
shown to be associated with exposure to immunosuppressive
agents or HIV infection [2]. Cervical intraepithelial neoplasia
(CIN) and cervical cancer occur more frequently in
women who are immunosuppressed, suggesting that both
local and systemic immune mechanisms may be involved
in the evolution of these diseases [3, 4]. In contrast, the
majority of HPV-positive cervical dysplastic lesions have
been reported to resolve spontaneously in immune
competent hosts [5].
The increased frequency of lymphocytes in cervical
carcinomas implies a key role of a cellular anti-tumor
response [6]. In fact, T-cell-mediated activity plays an
important role in both anti-tumor and anti-viral immunity.
In particular, the optimal T lymphocyte response is
mediated by the balance between CD28 and CTLA-4
molecules. CD28 is constitutively expressed in both CD4+
and CD8+ T cell subsets, and functions as the main
costimulator of T cells. Its structural homologue CTLA-4
is transiently induced upon activation, and is responsible
for termination of an ongoing immune response. Any
dysregulation of expression of CD28 and CTLA-4
molecules might result in impaired T cell functions.
The interaction of immunological genes for CD28,
CTLA-4, and IFN-gamma in susceptibility to cervical
cancer has been recently demonstrated [7]. In particular,
the two-locus combination of IFNG+874(AA) genotype
with CD28+17(TT) or CTLA-4-319(CC) affecting protein
expression was recently found to be associated with
cervical cancer susceptibility [7, 8]. Those findings
strongly suggest a relation between CD28, CTLA-4, and
IFN-gamma, and their importance in cervical carcinoma
development [7, 9]. Therefore, we assessed the pattern of
expression of both CD28 and CTLA-4 molecules in
freshly isolated and ex vivo stimulated peripheral blood
(PB) T cells from patients with advanced cervical cancer.
Wealsoexaminedtheabilityof PBMCstosecreteIFN-gamma
under non-stimulation and stimulation conditions. All
results were compared to those obtained from healthy
individuals.
Our study shows for the first time that patients with
advanced stages of cervical cancer could be immunosup-
pressed due to a dysregulated pattern of costimulatory
CD28 and inhibitory CTLA-4 molecules expression in
PB T cells.
Materials and Methods
Patients
The study was performed on a group of 22 women with
clinically definite CC in stages as follows: III (17 patients)
and IV (5 patients). Stage of the disease was classified
according to the International Federation of Gynecology
and Obstetrics (FIGO). Median age of patients was 54
(range 38–74). Patients were treated at the Department of
Oncology and Gynecological Oncology in Wroclaw
Medical University. All cases of cervical cancer were
histologically defined as cervical squamous cell carcinoma
(CSCC).
Blood samples were taken from patients before therapy.
Standard treatment of cervical cancer stage III-IVA was
radiation combined with concurrent chemotherapy. In
particular, all patients were treated by external beam
radiotherapy (EBRT) according to conformal planning.
The target volume covered the tumor with a sufficient
margin of vagina and regional lymph nodes. The dose of
EBRT was approximately 50.4 Gy in conventional
fractionation of 1.8 Gy daily. Conformal boosts of an
additional 10–15 Gy were applied (limited volumes of
gross unresected adenopathy). We used conformal treatment
with 18 MeV photon beams generated from a Varian linear
accelerator. For the majority of patients receiving EBRT,
concurrent cisplatin-based chemotherapy, every-7-days
regimen, 40 mg/m
2 was also administered.
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using intracavitary applicators depending on the patient
and tumor anatomy. The treatment was initiated toward
the latter part of external beam radiotherapy, after
sufficient regression of the tumor. We used HDR micro-
Selectron (Nucletron). The dose of brachytherapy was
usually 30 Gy/3 fr. Cervical cancer patients in stage IV B
received palliative radiotherapy, chemotherapy or symptom
treatment.
The control group consisted of 17 healthy age-matched
women with the median age 48 (range 28–70). Informed
consent was obtained from each individual. The study was
approved by the local ethics committee.
Cell Isolation and Culture Conditions
Peripheral blood mononuclear cells (PBMCs) were
s e p a r a t e db yb u o y a n td e n s i t y - g radient centrifugation on
Lymphoflot (Biotest, Germany) from freshly drawn
peripheral venous blood and washed 3 times in
phosphate-buffered saline (PBS) (without Ca
2+ and Mg
2+).
Cells were suspended at 1×10
6 PBMCs/ml in RPMI-1640
medium (Gibco, Paisley, UK) supplemented with 10% fetal
calf serum (Flow Laboratories, UK), 2 mmol/l L-glutamine
and 50 μg/ml gentamicin (Gibco), and cultured with 5 ng/ml
of anti-CD3 monoclonal antibodies (MoAbs) (Ortho,
Neckargemund, Germany) and 500 U/ml of rIL-2 (Eurocetus,
Amsterdam,TheNetherlands).Inourmodel,rIL-2servedasa
second signal to induce an optimal immune response. Control
cultureswithout stimulantswereincluded ineach experiment.
The cultures were incubated at 37°C in a humidified
atmosphere containing 5% CO2 for 24, 48, and 72 h. Culture
supernatants were stored at −80°C until the time of testing.
CD28 and CTLA-4 Staining and Flow Cytometric Analysis
CD28 and CTLA-4 expression was studied on the freshly
isolated and cultured CD3+CD4+ and CD3+CD8+ cells
by a triple immunostaining method. Briefly, for detection of
CD28 and membrane CTLA-4 molecules, the cells were
washed twice in PBS, divided into tubes at a concentration
of 5×10
5 cells per tube, stained with anti-CD3/PerCP, anti-
CD4/FITC or anti-CD8/FITC, and anti-CD28/RPE or anti-
CTLA-4 (CD152)/RPE monoclonal antibodies (MoAbs)
(Becton Dickinson), and incubated for 30 min at 4°C in the
dark. Excess unbound antibodies were removed by two
washes with PBS. Following these washes, the cells were
resuspended in PBS and analyzed by flow cytometry
using a FACSCalibur flow cytometer (Becton Dickinson).
For intracellular detection of CTLA-4, the cells were first
incubated for 30 min at 4°C in the dark with pure anti-CTLA-
4 MoAb to block surface CTLA-4 molecules, then fixed and
permeabilized according to the manufacturer’s recommenda-
tions, and then stained as described above. Negative controls
were always done by omitting the MoAb and by incubating
the cells with mouse Ig of the same isotype as the MoAbs
conjugated with PerCP, FITC or RPE. At least 10,000 events
per sample were analyzed. All PBMCs were included in the
forward scatter/side scatter (FwSc/SSc) gate. Of the acquired
10,000 events, at least 1,500-2,000 were analyzed in the final
CD28- or CTLA-4-staining histograms. The results were
expressed as the proportion of CD28-positive CD3+CD4+ or
CD3+CD8+ cells and CTLA-4-positive CD3+ lymphocytes.
The CellQuest program was used for statistical analysis of the
acquired data.
Assessment of IFN-γ Concentration
For IFN-gamma measurement, we cultured PBMCs for 72
h in medium alone or with the addition of anti-CD3+rIL-2
in concentrations described above. Supernatant samples
collected from studied groups were frozen (−70°C) until
analyzed. IFN-γ concentration in non-stimulating and
stimulating culture supernatants was determined by
enzyme-linked immunosorbent assay (ELISA) using R&D
Systems reagent kit (UK) according to the manufacturer’s
recommendations. Each sample was run in duplicate. The
values were expressed as picograms per milliliter relative to
a set of standards supplied with the kit.
Statistical Analysis
Before further analysis, data were checked for normal
distribution using the Shapiro-Wilk test. As the data
showed non-parametric distribution, Mann–Whitney U test
for comparison of the unpaired data was used. The
summary statistics are given as the mean±SD. The level
of statistical significance was set as p≤0.05.
Results
Expression of Costimulatory CD28 Molecule
on Freshly Drawn and anti-CD3+rIL-2-Stimulated
CD4+ and CD8+ T Lymphocytes from Cervical Cancer
Patients and Healthy Controls
To examine the magnitude of functional T helper (Th) and
T cytotoxic (Tc) lymphocytes in PB of patients and controls,
we estimated the expression of CD28 molecule within both
CD4+andCD8+Tcellpopulationsinthestudiedgroups.The
results are shown inTable 1 and Figs. 1 and 2. We found that
the mean proportion of PB CD4+CD28+ T cells was
significantly lower in cervical cancer (CC) patients than in
controls. The decrease in CD28-positive cells within the
CD8+ T cell subset was even more pronounced. Similarly to
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observed in patients a marked decrease in the mean
frequency of CD4+CD28+ T cells, which returned to pre-
stimulation values after 48 h, and remained unchanged after
72 h of culture (Fig. 2a). The only difference between CC
patients and controls was markedly diminished proportions
of CD4+CD28+ T cells in CC women at each time point
tested. In contrast, the frequencies of CD8+CD28+ Tcells in
the patient group did not change during ex vivo stimulation,
and maintained stable values, which were significantly lower
at different time points of culture compared to controls
(Figs. 1 and 2b).
The analysis of the pattern of CD28 expression on CD4+
and CD8+ PB T cells indicates that patients with advanced
CC may exhibit a profound defect of the CD28-mediated
costimulatory pathway. Thus, abnormal CD28 expression
on effector T cells may contribute to inadequate activation
and dysfunction of PB lymphocytes in CC.
Expression of Inhibitory CTLA-4 (CD152) Molecule
on Freshly Drawn and anti-CD3+rIL-2-Stimulated
T Lymphocytes from Cervical Cancer Patients
and Healthy Controls
Since homeostasis in the immune responses results from a
balanced interplay between CD28 and CTLA-4, we
analyzedwhethertheobserveddysregulatedCD28expression
might have an impact on the pattern of CTLA-4 expression
in PB T cells from CC patients. The results are shown in
Table 1 and Figs. 3 and 4.I np a t i e n t s ,w ef o u n dm a r k e d l y
heightened mean proportions of both CD4+ and CD8+ PB
T cells with surface expression of CTLA-4 molecule
compared to controls. Furthermore, there were no statistically
significant differences between the magnitude of CD4+
CTLA-4+ and CD8+CTLA-4+ T cells in all patients at each
time point tested (data not shown), suggesting similar kinetics
and levels of CTLA-4 expression in all T lymphocytes
without distinction between both subpopulations. Thus,
we decided to continue the analysis of its expression on
CD3+−gated lymphocytes, in addition, with regard to
CTLA-4 cellular distribution. Ex vivo stimulation led to
a further increase in the frequency of T cells co-expressing
CTLA-4 with the maximum value after 24 h of culture. On
subsequent days of the stimulating culture, we observed a
gradual decline in the proportions of CTLA-4+ T cells.
However, the levelsoftheir expressionremained significantly
higher than those observed in controls at each time point
tested (Figs. 3 and 4a). In healthy individuals, the mean
frequencies of CTLA-4+ T cells (Table 1, Figs. 3 and 4a)
gradually increased under stimulation conditions, and
reached a maximum level after 72 h, which was in sharp
contrast to CC patients.
From these results it seems that in advanced CC,
impaired CD28 expression is accompanied by an abnormal
pattern of inhibitory CTLA-4 molecule expression, which
may contribute to earlier and stronger induction of the
CTLA-4-mediated down-regulatory pathway in PB T cell
responses upon antigen stimulation.
Table 1 Mean percentages and standard error of peripheral blood lymphocytes expressing CD28 and CTLA-4 in CC patients and healthy controls
freshly drawn cells% 24 h stimulated% 48 h stimulated% 72 h stimulated%
CC patients (n=22)
CD3+CD4+CD28+ 70.2±19.1
**,a 56.1±15.2
*,a,b 70.8±14.6
*,b 68.2±15.2
*
CD3+CD8+CD28+ 21.2±13.3
†† 23.4±9.8
† 26.3±9.1
† 25.1±12.9
††
CD3+sCTLA-4+ 15.2±3.2
‡‡,a 25.1±4.1
‡‡,a 24.0±3.9
‡‡,c 17.6±2.7
‡,c
CD3+cCTLA-4+ 11.2±1.9
#,a 32.3±6.4
##,a,b 44.1±5.1
##,b 47.2±4.7
##
Healthy controls (n=17)
CD3+CD4+CD28+ 93.4±8.2
**,a 70.0±7.9
*,a,b 89.2±6.8
*,b 87.3±8.1
*
CD3+CD8+CD28+ 70.2±6.9
††,a 53.1±4.5
†,a,b 66.2±6.1
†,b 69.3±5.4
††
CD3+sCTLA-4+ 1.9±0.5
‡‡,a 3.5±0.9
‡‡,a,b 4.8±1.1
‡‡,b,c 7.9±1.9
‡,c
CD3+cCTLA-4+ 1.4±0.2
#,a 2.9±0.8
##,a 3.5±1.1
##,c 6.2±1.5
##,c
*Comparison between CC patients and healthy controls. One symbol indicates p<0.05; two symbols p<0.04.
†Comparison between CC patients and healthy controls. One symbol indicates p<0.01; two symbols p<0.001.
‡Comparison between CC patients and healthy controls. One symbol indicates p<0.01; two symbols p<0.00001.
#Comparison between CC patients and healthy controls. One symbol indicates p<0.0001; two symbols p<0.00001.
aComparison between freshly drawn cells and 24 h stimulated cells; p<0.04.
bComparison between 24 h stimulated cells and 48 h stimulated cells; p<0.05.
cComparison between 48 h stimulated cells and 72 h stimulated cells; p<0.02.
sCTLA-4 – surface CTLA-4; cCTLA-4 – cytoplasmic CTLA-4
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in Cytoplasmic Compartment of Freshly Drawn
and anti-CD3+rIL-2-Stimulated T Lymphocytes
from Cervical Cancer Patients and Healthy Controls
To find out whether the dysregulated surface CTLA-4
expression in CC patients might result from enhanced
recycling of the CTLA-4 molecule to the cell membrane,
we performed intracellular staining for cytoplasmic CTLA-4
in both freshly drawn and ex vivo stimulated T cells. The
results are shown in Table 1 and Fig. 4b. Likewise, we
observed markedly up-regulated proportions of PB T
lymphocytes with intracellular CTLA-4 content in CC
patients compared to controls. In the culture with stimulants,
we found significantly heightened CTLA-4 expression at
each time point tested as it was shown in the case of surface
CTLA-4 (Fig. 4b). Of note, the kinetics of cytoplasmic
CTLA-4 expression in CC patients were seen to be different
Fig. 1 CD28 expression in peripheral blood CD8+ T cells from
patients with CC and from healthy controls before and after 24 h, 48
h and 72 h stimulation with anti-CD3 MoAb+rIL-2. The dot plots and
histograms show representative data, illustrating the analysis method
for identification of CD3+/CD8+ cells expressing CD28 following
three-color staining. (a) The dot plots show the forward scatter/side
scatter (FSC/SSC) distribution and the gate (region R1) was used to
select lymphocytes for analysis. The R1 gated events were then
analyzed for CD3/PerCP and CD8/FITC staining and double-positive
cells (CD3+CD8+) were gated (region R2). The dot plots show
representative data from one patient with CC. (b) The final histo-
grams. The double-gated populations were then analyzed for CD28/
RPE. The gray histograms represent the isotype controls. The numbers
located on the histograms represent the percentage of CD3+CD8+
cells expressing CD28 molecule
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former at 72 h.
These results allow us to exclude disturbed intracellular
trafficking of CTLA-4 as a cause of up-regulated surface
CTLA-4 expression in CC patients.
Measurement of IFN-Gamma Concentrations
in Supernatants from the Culture of PBMCs in Medium
Alone and with Addition of anti-CD3+rIL-2
As IFN-gamma was suggested to be associated with CD28
and CTLA-4 molecules in development of CC, we
estimated IFN-gamma levels in supernatants from the
culture of PBMCs in both studied groups. Although we
observed increased capacity for spontaneous production of
IFN-gamma in the culture in medium alone in CC patients
compared to healthy individuals (179.1±144.6 pg/ml vs.
151.7±213.2 pg/ml), the differences between studied
groups were not statistically significant. In contrast,
significantly increased IFN-gamma concentrations secreted
by stimulated cells from patients with advanced CC
compared to controls were found (1906.5±1548.2 pg/ml vs.
616.4±363.0 pg/ml; p=0.04).
Discussion
Our study shows that advanced cervical cancer patients
have a variety of defects reflecting impaired T cell
immunoregulatory circuits. Herein, we report for the first
time significant dysregulation in the percentages of PB T
cells expressing suppressor CTLA-4 and costimulatory CD28
molecules before and after ex vivo stimulation. Abnormal
expression of both CTLA-4 and CD28 in peripheral
nonmalignant T lymphocytes has been demonstrated in
some malignancies [10–13]. The literature lacks reports
on the pattern of expression of these molecules in
advanced cervical cancer patients. We found a marked
Fig. 2 The mean percentage of
peripheral blood CD4+CD28+
T cells (a) and CD8+CD28+
T cells (b) before and after
ex vivo 24, 48 and 72 h of
anti-CD3+rIL-2 stimulation in
CC patients and healthy controls
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isolated from PB of patients as compared with healthy
individuals. We also observed markedly diminished
proportions of CD28-positive cells within both T cell
subpopulations, more pronounced in the CD8+ subset.
Since CTLA-4 expression is transiently induced upon
stimulation, it is considered to be an activation marker.
Thus, its higher expression reflects systemic activation status
in the periphery during progression of cervical cancer. Our
additional finding of markedly decreased proportions of PB
CD4+ and CD8+ T cells with CD28 expression in patients
strengthens the suggestion that these lymphocytes are in a
partial state of in vivo activation. This statement results from
the observation that the CD28 molecule is lost by Tcells after
repeated stimulation in long-term culture [14]. Elevated
concentrations of chemical indicators of systemic immune
activation, such as neopterin, have also been reported in
patients with gynecological carcinomas, including cervical
cancer, but not in women with benign neoplasms or
precancerous disorders [15].
Fig. 3 Surface CTLA-4 expression in peripheral blood CD3+ cells
from patients with CC and from healthy controls before and after 24 h,
48 h and 72 h stimulation with anti-CD3 MoAb+rIL-2. The dot plots
and histograms show representative data, illustrating the analysis
method for identification of CD3+ cells expressing CTLA-4 molecule
following double-color staining. (a) The dot plots show the forward
scatter/side scatter (FSC/SSC) distribution and the gate (region R1)
was used to select lymphocytes for analysis. The R1 gated events were
then analyzed for CD3/FITC staining and CD3-positive cells were
gated (region R2). The dot plots show representative data from one
patient with CC. (b) The final histograms. The double-gated
populations were then analyzed for CTLA-4 expression. The gray
histograms represent the isotype controls. The numbers located on the
histograms represent the percentage of CD3+ cells expressing surface
CTLA-4
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not seem to result from cellular trafficking, since it is
accompanied by a CTLA-4 increase in the cytoplasmic
compartment, suggesting rather the up-regulated CTLA-4
gene activity during in vivo continuous stimulation with
cancer- and/or viral-associated antigens. We also hypothesize
that heightened levels of CTLA-4 in T cells may result,
at least in part, from genetic disturbances. The relation of
its increased expression with higher frequency of the T allele
at position −319 in the CTLA-4 promoter region has been
previously demonstrated [16]. A recent study by our group
showed significantly higher frequencies of both the T allele
and the CT+TT genotype in Polish cervical cancer women
compared with healthy controls [17]. We also demonstrated
that this genotype increased the risk of disease approximately
twofold [17]. The same observation was found by Su et al.
[18] in Taiwanese women suffering from cervical cancer,
especially in those who were HPV-positive.
Since the loss of CD28 expression was found to be
accelerated by type I IFN released during viral infections
[19], we cannot exclude the influence of HPV infection on
the decreased expression of CD28, at least in the group of
cervical cancer patients studied. It has also been suggested
that one of the mechanisms leading to diminished CD28
expression may be secretion of immunosuppressive
cytokines by tumors. The impact of TNF-alpha on the
repression of the transcriptional activity of the CD28
gene promoter has been previously demonstrated [20].
T h ec o n n e c t i o no fi m p a i r e dC D 2 8e x p r e s s i o no nP BT
cells with TNF-alpha concentration seems to be possible
in the light of findings that serum levels of this cytokine
produced by neoplastic cells were markedly increased in
cervical cancer patients and correlated with the stage of
the disease [21–24].
We also observed in patients dysregulated kinetics of
both CD28 and surface CTLA-4 expression after ex vivo
Fig. 4 The mean percentage
of peripheral blood T cells
expressing surface CTLA-4
(CD3+sCTLA-4+ cells)
(a) and cytoplasmic CTLA-4
(CD3+cCTLA-4+ cells)
(b) before and after ex vivo 24,
48 and 72 h of anti-CD3+rIL-2
stimulation in CC patients and
healthy controls
486 A. Kosmaczewska et al.stimulation. In contrast to healthy individuals, who exhibit
maximum surface CTLA-4 expression at 72 h of stimula-
tion, in patients with cervical carcinoma the peak of its
expression was observed at 24 h, with a gradual decline to
pre-stimulation values at 96 h. Heightened proportions of
surface CTLA-4 positive T cells in cervical cancer might be
of biological relevance consistent with the notion that only
surface CTLA-4-mediated signals are capable of inhibiting
the ongoing T cell responses. In the case of CD28, under
normal stimulation conditions, its expression rapidly
down-regulated within the first 24 h, and returned to
baseline levels at 48 h of culture [12, 25]. In the CD8+ T
cell population from cervical cancer patients, CD28
expression remained at a stable decreased level at each
time point tested. However, the kinetic pattern of CD28
expression within CD4+ T cells was similar to that
observed in controls, except for significantly lower mean
frequency of CD4+CD28+ T cells in the stimulation
period. Based on the fact of reciprocal regulation of CD28
and CTLA-4 expression on both mRNA and protein levels
during the first 24 h of stimulation [25], it can be
suggested that the loss of CD28 expression may deliver
a much stronger stimulus for CTLA-4 gene induction
resulting in heightened levels of protein expression on T
cells in advanced cervical carcinoma.
Dysregulated expression of costimulatory CD28 and
inhibitory CTLA-4 molecules within PB T cells strongly
suggests their possible impact on the biology of the effector
T cell responses in cervical cancer leading to abnormalities
in systemic cellular immunity during disease progression.
The demonstration of a direct correlation between
immunological competence of the host and clinical outcome
for patients harboring cervical cancer has been previously
reported [26]. It has been demonstrated that up-regulated
CTLA-4 expression on circulating effector cytotoxic
CD8+ T cells reflects the state of T cell exhaustion
due to persistent antigenic stimulation [27, 28]. Further-
more, blockade of CTLA-4 can reverse CD8+ T cell
dysfunction in a CD28-dependent manner. This functional
effect is mediated by CD8+CD28+ T cells, and indepen-
dently from CD4+FoxP3+CTLA-4+ regulatory T cells
(Treg) [28]. Thus, detection of CD28 expression within
the CD8+ T cell subset provides a marker for reversible
functional exhaustion of these cells. Our observation that
the loss of CD28 expression is more pronounced in the
CD8+ T cell population strongly suggests affected
cytotoxic effector function in progressive cervical cancer,
influencing the defense against virus-induced tumors [29]
and clinical response to chemotherapy [30].
The generation of a specific cytotoxic T cell response is
known to depend on sufficient help from activated CD4+ T
cells. It has been shown that failure of the anti-tumor
response can result from inadequate activation of tumor-
specific CD4+ T helper cells [31]. In the light of those
findings, the effective anti-tumor and anti-viral action of
cytotoxic CD8+CD28+ T cells in cervical cancer patients
enrolled in our study might be complicated by dysregulated
expression of both CD28 and CTLA-4 within the CD4+ T
helper cell population, which may lead to its dysfunction
[32, 33].
Recent evidence indicates, however, that both CD28 and
CTLA-4 are also important in the homeostasis and function
of the suppressive T cell populations, termed regulatory
and/or suppressor T cells [34–36], as continuous antigen
stimulation leads to generation of highly suppressive
adaptive CD4+FoxP3+ as well as CD8+FoxP3+ regulatory
T cells (Treg) [37]. Increased levels of CTLA-4 molecules
may promote generation and function of adaptive CD4+
FoxP3+ T cells in addition to their other inhibitory effects
[38]. However, their role in the induction of CD8+FoxP3+
T cells is still controversial. CTLA-4 was found to be
constitutively expressed on the cell surface as well as in the
cytoplasmic compartment of Treg cells [39]. Up-regulated
CTLA-4 expression within both T cell subsets found in our
study seems to strengthen immunosuppressive action of
Treg cells in advanced cervical cancer. This suggestion is in
accordance with the observation on the increased frequency
and suppressive activity of Treg cells in PB from women
with cervical cancer [40].
Recent studies revealed that CD8+ T cells exhibit a
cytotoxic activity in conjunction with positive expression of
CD28, but show a suppressive action in the presence of
negative labeling [41]. Our report shows that advanced
cervical cancer patients exhibit a significantly increased
population of PB immunosuppressive T cells with the
phenotype CD8+CD28-, and this observation is in accor-
dance with studies performed in other cancer patients [36].
These suppressor T cells originate and function in the
presence of IL-10 [42], found at high concentrations in sera
from patients with advanced stages of cervical cancer [43,
44]. CD8+CD28- T cells suppress proliferation of the
effector T cells and the functional activity of cytotoxic T
lymphocytes, thus diminishing the defense against tumors
[41, 45].
In our study we also demonstrated increased levels of
stimulated IFN-gamma in supernatants from patients with
advanced cervical cancer and it was, in fact, an unexpected
notion. This phenomenon is difficult to explain in the light
of contradictory results. IFN-gamma-producing Th1 cells
were shown to promote the development of cell-mediated
immunity against viral infection as well as HPV-associated
neoplasms [46]. Therefore, the ability of reactive cells to
secrete intratumorally the immunostimulatory and anti-viral
cytokine IFN-gamma has been reported to be an indepen-
dent factor for disease-free survival in cervical cancer [47].
Preferential recruitment and accumulation of Th1 cytokine-
Dysregulated Expression of CD28 and CTLA-4 in Cervical Cancer 487secreting cells to the invasive cervical cancer lesions in
early stage cervical cancer patients suggested that these
cells could play an important role in local anticancer
immunity [48]. Several papers have indicated a beneficial
effect of a high Th1/Th2 ratio in the case of various other
cancers as well [49–53]. The up-regulated ability of
stimulated PBMCs to secrete IFN-gamma found in patients
from our study may likely suggest that the population of PB
Tcells in cervical cancer patients is in activated form due to
exposure to viral and/or tumor antigens. However, a few
papers have demonstrated a role of Th1 shift in the tumor
promotion and immunosuppression [54–57]. It has been
reported that increased production of IFN-gamma in
tumor-associated inflammatory cells may contribute to
tumor growth and disease progression [56]. In lung
cancer, the presence of tumor cells or tumor-derived
factors in peripheral blood following tumor burden favors
the differentiation of PB T cells towards tumor-specific
Th1- and Tc1-producing IFN-gamma cells, and seems to
b ean e g a t i v ep r o g n o s t i cf a c t o r[ 57]. In this context, we
cannot exclude that increased IFN-gamma production
seen in studied patients with advanced disease could
also reflect the tendency to neoplastic dissemination.
Further experiments are required to settle the above
contradiction.
In summary, our report provides the first evidence that
patients with advanced cervical cancer exhibit dysregu-
l a t e de x p r e s s i o no fm o l e c u l e sp l a y i n gak e yr o l ei nt h e
balanced cellular immune responses. These abnormalities
likely have a considerable impact on the development of
systemic immunosuppression involved in cervical cancer
progression.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
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